UCB announced on 5/14/18 that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) Briviact (... read more
UCB announced on 5/14/18 that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) Briviact (... read more
Synaffix B.V. announced today the expansion of its Scientific Advisory Board (SAB) with the addition of Dr. John M. Lambert, the former Chief Scientific Officer of ImmunoGen, Inc.
Dr.... read more
AstraZeneca and MedImmune, announced on 5/11/18 top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary... read more
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), announced on 5/11/18 that the first patient has been dosed in the Phase 1/2, first in-human trial of KB103, a first-in-class topical gene therapy... read more
